Avalon Pharmaceuticals to Present at Bear Stearns 20th Annual Healthcare Conference

GERMANTOWN, Md., Aug. 30  /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. (NASDAQ:AVRX), today announced that Kenneth C. Carter, Ph.D., President and CEO, is scheduled to provide an update on the Company at the Bear Stearns 20th Annual Healthcare Conference.

The conference will be held at the Grand Hyatt Hotel in New York City on Sept. 10-11, 2007. Dr. Carter is scheduled to present on Tuesday, Sept. 11th, at 9:30 a.m. EDT.

The presentation will be available live via webcast and can be accessed through the investor page of Avalon Pharmaceuticals' website at: http://www.avalonrx.com/. An archive of the presentation will be available for 90 days following the conference.

About Avalon Pharmaceuticals

Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon's lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development.  Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the survivin and Myc pathways and partnerships with Merck, MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx(R) is the company's proprietary platform which is based on large-scale biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable."  Avalon is headquartered in Germantown, Md.

  Contacts:
  Avalon Pharmaceuticals, Inc.            Russo Partners, LLC
  C. Eric Winzer                          Wendy Lau (Media)
  Executive Vice President &              Tel: [phone]
  Chief Financial Officer
  Tel: [phone]                     The Trout Group LLC
  Fax: [phone]                     Chad Rubin (Investors)
  Email:                 Tel: [phone]


DATASOURCE: Avalon Pharmaceuticals, Inc.



CONTACT: C. Eric Winzer, Executive Vice President & Chief Financial

Officer of Avalon Pharmaceuticals, Inc., [phone], Fax:

[phone], ; or Media, Wendy Lau of Russo Partners,

LLC, [phone]; or Investors, Chad Rubin of The Trout Group LLC,

[phone], both for Avalon Pharmaceuticals, Inc.



Web site:  http://www.avalonrx.com/ 

Copyright